LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Joint Statement for an Ambitious Horizon Europe Programme

16/09/2019
OTHER

Joint Statement for an Ambitious Horizon Europe Programme

Joint statement of 93 associations representing key European research & innovation stakeholders calling for ambitious Horizon Europe programme.

We, the undersigned 93 European associations representing key European research & innovation stakeholders, hereby urge the EU Institutions to make research, development and innovation (RD&I) a priority within the next Multiannual Financial Framework 2021-2027. We call on the Council of the EU to raise the budget allocated to the Horizon Europe programme to at least €120 billion (in 2018 prices), of which at least 60% should be dedicated to the “Global Challenges and European Industrial Competitiveness” pillar.

We very much welcomed the EU Institutions’ efforts to reach a partial agreement on Horizon Europe. This enabled to start the preparation for the implementation of the programme in time. The European innovation community is committed to be actively involved in a concrete co-creation process towards Horizon Europe’s successful implementation. However, the programme will need an adequate budget at the level of its ambitions. The European Parliament has already taken a stand to prioritise RD&I in the EU budget. Similarly, we encourage Member States to support a budget of at least €120 billion (in 2018 prices). This would ensure that Horizon Europe delivers on its promises to:

- Boost Europe’s future growth, employment and competitiveness. As recognised in the European Industrial Strategy, RD&I is the real engine of growth. Getting a sufficient budget for Horizon Europe would not only mean the creation of up to 100,000 jobs in RD&I activities between 2021-2027, but also €11 of GDP in return for each €1 invested over 25 years (1).

- Secure Europe’s seat amongst the frontrunners of the technological revolution. While the international competition for innovative solutions escalates, European RD&I expenditure remains relatively low compared to our global competitors. The target of 3% of GDP invested in R&D should now become a reality.

- Develop and scale up the technologies that will power our continent in the 21st century. Horizon Europe needs to build on the successes of Horizon 2020 and scale up the investments made so far. As stated by the Lamy Group, we need a budget that paves the way for Europe to deliver on the key societal challenges of today and anticipate those of tomorrow.

- For such promises to be fulfilled, excellent cross-border collaborative RD&I with impact needs to be prioritised within Horizon Europe. EU Members States should allocate a budget share of at least 60% of Horizon Europe’s total budget to its pillar II - Global Challenges and European Industrial Competitiveness. This pillar is the truly collaborative part of Horizon Europe, breaking silos to promote the flow of knowledge between public research and industry. This Horizon Europe pillar II is crucial to:

- Build long-term trust-based partnerships amongst a wide variety of European RD&I actors, which is an indispensable element to strengthen Europe’s RD&I ecosystems and industrial value-chains. This would ensure the Industry’s uptake of novel technologies and scale up into new solutions, products and services, improving people’s well-being and quality of life, and increasing European competitiveness.

- Reduce risk and uncertainty and stimulate business investment in Europe by demonstrating the EU’s support to technology-intensive sectors (including Key Enabling Technologies). This would give the right incentive to private innovators to invest in Europe, rather than abroad.

- Join forces at EU level to better face the great challenges of today and deliver on the Sustainable Development Goals. The Horizon Europe pillar II, containing missions and partnerships, especially aims at this ambitious objective and therefore needs to be supported by an adequate budget. We, the undersigned associations, are ready to further discuss these recommendations with the EU Institutions. We are fully convinced that Europe has the potential to lead the global innovation race and to remain a model of economic and social prosperity. For that, Europe needs to strongly invest in pan-European collaborative RD&I.

Download the full publication below.

Joint Statement for an Ambitious Horizon Europe Programme


Download
Share
Communications Team
Communications Team

Related posts

12/11/2025

EuropaBio response to the EU Biotech Act public consultation


Read more
05/11/2025

EuropaBio recommendations for the Circular Economy Act


Read more
02/10/2025

Public Consultation Response to the European Innovation Act proposal


Read more

Important links

  • EuropaBio response to the EU Biotech Act public consultation
  • EuropaBio recommendations for the Circular Economy Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.